Ptc Therapeutics (PTCT) Receivables - Other (2023 - 2024)

Ptc Therapeutics (PTCT) recorded quarterly Receivables - Other of $800000.0 in Q1 2024, up 300.0% quarter-over-quarter from $200000.0 in Q4 2023.

Ptc Therapeutics (PTCT) Receivables - Other (2023 - 2024) Analysis & Trends

Ptc Therapeutics' Receivables - Other history runs 2 years deep, the most recent figure standing at $800000.0 for Q1 2024.

In Q1 2024, Receivables - Other changed N/A year-over-year to $800000.0; the TTM figure through Mar 2024 stood at $800000.0 (changed N/A YoY), while the FY2023 annual figure was $200000.0, changed N/A from the prior year.
Receivables - Other was $800000.0 for Q1 2024 at Ptc Therapeutics, up from $200000.0 in the prior quarter.
In the past five years, Receivables - Other ranged from a high of $1.4 million in Q3 2023 to a low of $200000.0 in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Ptc Therapeutics	6.51 Bn	4.61 Bn	244.52 Mn

Download Data